Some decades ago, Francis Crick presciently predicted that in order for scientists to elucidate the ''neuronal codes'' that specify behavior, perception, and consciousness, ''a method (is needed) by which all neurons of just one type could be inactivated, leaving the others more or less unaltered'' (Crick, 1979) . Now, of course, both optogenetic (Zhang et al., 2007) and chemogenetic (Armbruster et al., 2007) technologies are widely available for silencing neurons ''of just one type.'' Simply inhibiting cell body firing and observing the resulting behavioral phenotype, unfortunately, does little to elucidate which specific projections or target areas might be responsible for the observed effects (see Figure 1A) . Ideally, what is needed is a technology that can specifically and reversibly silence presynaptic nerve terminals, thereby ''silencing synapses'' projecting to distinct neuronal populations ( Figure 1B) . A technological leap forward is now reported by Stachniak et al. (2014) , who via clever modifications of the DREADD chemogenetic platform achieved synaptic silencing.
As first described, the hM4Di-DREADD, when stimulated by clozapine-N-oxide (CNO), activates G protein inwardly rectifying potassium (GIRK) channels, thereby hyperpolarizing and attenuating neuronal activity (Armbruster et al., 2007) . hM4Di is now routinely used as a tool to diminish the activity of genetically defined neurons in vitro and in vivo (Atasoy et al., 2012; Ferguson et al., 2011; Krashes et al., 2011; Ray et al., 2011; Carter et al., 2013) . The robust effects of hM4Di activation on physiology (see Ray et al., 2011 for example) and behavior (see Carter et al., 2013 for instance) have been difficult to reconcile with the relatively modest ability of hM4Di to hyperpolarize and attenuate neuronal firing in vitro (see, for instance, Ferguson et al., 2011; Krashes et al., 2011; Ray et al., 2011) . Here, Stachniak et al. (2014) confirm that hM4Di activation leads to hyperpolarization and attenuation of neuronal firing but also discovered a much more potent action of hM4Di as an effective synaptic silencer in slice preparations and in vivo. It is this silencing of synaptic transmission that will ultimately expand the utility of DREADDbased technology for deconstructing the neuronal code.
Using postsynaptic current as the readout, they first tested whether the CNO-induced activation of hM4Di in a presynaptic neuron suppresses synaptic transmission to postsynaptic neurons located in the same or in different layers of the cortex. They discovered that CNO-induced activation of hM4Di L2/3 presynaptic cortical neurons robustly inhibited the postsynaptic current in both L2/3 neurons and L5 neurons. They also demonstrated that this inhibition of the postsynaptic current was not due to blockade of either the initiation or the propagation of the axonal action potential. Instead, hM4Di appeared to act by suppressing L2/3 synaptic glutamate release. Importantly, neither CNO administered in control slices nor basal hM4Di activity had any significant effect on synaptic glutamate release from L2/3 glutamatergic neurons.
To determine whether this ''synaptic silencing'' by hM4Di could be useful for studies in vivo, Stachniak et al. (2014) chose a well-characterized and popular neural circuit for food intake and examined synaptic transmission from Agouti-related peptide (AgRP)-expressing neurons in the arcuate nucleus of the hypothalamus (ARC) to paraventricular hypothalamic (PVH) neurons (Stachniak et al., 2014) . Prior studies showed that PVH neurons receive axonal projections from AgRP neurons and mediate food intake evoked by activation of AgRP neurons (Atasoy et al., 2012) . Stachniak et al. (2014) then coexpressed channelrhodopsin2 (ChR2) and hM4Di in AgRP neurons and examined the effect of CNO on light-evoked food intake. Astoundingly, they found that microinfusion of CNO above the PVH, but not in an area only 300-500 mm distant, reduced feeding by 50% during AgRP neuron photostimulation. Taken together, the results obtained from studies in the cortex and hypothalamus demonstrate that hM4Di can effectively suppress presynaptic transmission both ex vivo and in vivo. In support of this notion, a recent report (Mahler et al., 2014) showed that microinfusion of CNO suppresses terminal dopamine release in hM4Di-expressing dopaminergic axons.
As hM4Di is normally localized to both neuronal cell bodies and axons (Mahler et al., 2014; Zhu et al., 2014) , it would be more useful to target it specifically to the axonal compartment to achieve selective suppression of synaptic transmission. To achieve this, Stachniak et al. (2014) The study by Stachniak et al. (2014) addresses two important issues related to DREADD technology. First, they provide convincing evidence that activation of hM4Di in presynaptic terminals can suppress synaptic transmission without disturbing somatic or axonal membrane potentials. Therefore, hM4Di probably silences neuronal activity in vivo via both hyperpolarization and suppression of presynaptic neurotransmitter release in a manner analogous to that achieved by presynaptic G-protein-coupled receptors. This makes hM4Di unique among the currently available optogenetic and chemogenetic tools that silence neuronal activity via hyperpolarizing neurons to suppress action potentials. Second, they demonstrate that microinfusion of CNO into discrete brain regions is a reliable way to achieve very precise spatiotemporal control of neuronal activity-in agreement with a recent study (Mahler et al., 2014) .
This study also raises an intriguing question regarding the mechanism by which hM4Di inhibits presynaptic neurotransmitter release. Although GPCRs are known to be ubiquitously expressed on presynaptic terminals and to modulate synaptic neurotransmitter release, how hM4Di regulates neurotransmitter release is unknown. It is not likely via GIRKS as GIRK1 is primary localized in postsynaptic rather than presynaptic terminals (Drake et al., 1997) and GPCR agonist-induced presynaptic inhibition is unchanged in GIRK2 knockout mice (Lü scher et al., 1997). Conceivably, hM4Di could induce presynaptic silencing via inhibition of cAMP-mediated signaling, which has been shown to modulate the activity of voltage-gated calcium channels in a model system (Hilfiker et al., 2001 ). Alternatively, hM4Di could inhibit the SNARE exocytotic fusion machinery downstream of calcium entry through the action G protein bg subunits (Gerachshenko et al., 2005) .
Whatever the mechanism, it is clear that hM4Di can effectively suppress presynaptic transmission both ex vivo and in vivo, and this makes it useful for many applications. Further, the axon-selective hM4D NRXN variant developed in this study is an exceedingly useful tool to functionally dissect neuronal circuitry by the targeted inhibition of presynaptic transmission without compromising the activities of other synapses originating from the same neurons.
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Figure 1. Spatially Precise Synaptic Silencing
As shown in (A), hM4Di is expressed mainly in the cell bodies and axon. Systemic CNO administration leads to hyperpolarization and suppression of electrical activity (depicted in the diagram by the blackcolored neuron) in a prototypic glutamatergic neuron. As described by Stachniak et al. (2014) , a global suppression of presynaptic glutamate release also occurs (black synaptic terminals) via synaptic silencing. The net effect is less excitatory drive of anatomically distinct neurons (which are colored blue to indicate lower excitatory drive). In (B), a glutamatergic neuron expresses hM4D NRXN mainly in axonal projections. Here a microinfusion of CNO does not induce somatic hyperpolarization and as a result the overall activity of the neuron is unchanged (colored yellow indicating robust spontaneous activity). Microinfusion of CNO suppresses presynaptic release of glutamate, leading to less excitatory drive of only neurons in the region perfused (blue) without altering activity of other neurons (red).
How do neurons and networks achieve their characteristic electrical activity, regulate this activity homeostatically, and yet show population variability in expression? In this issue of Neuron, O'Leary et al. (2014) address some of these thorny questions in this theoretical analysis that starts with the Central Dogma.
Two seemingly opposed conceptual threads wind through current experimental and theoretical analyses of neuronal and network activity. On the one hand, neuronal and network activity regimes are remarkably robust and can homeostatically rebound from long-term perturbation. This was first described in pioneering theoretical studies and experimental work employing neurons isolated from the stomatogastric nervous system of crustaceans. Such homeostatic plasticity has now been observed and modeled in cell culture, brain slices, and in vivo across invertebrates and vertebrates and has led to important concepts such as synaptic scaling (Davis, 2006; LeMasson et al., 1993; Marder and Goaillard, 2006; Turrigiano, 2007; Wenner, 2014) . An evolving notion is that intracellular [Ca 2+ ]-fed by Ca 2+ entry through voltage-gated Ca 2+ channels or Ca 2+ -permeable synaptic channels-serves as an effective signal of neuronal and network activity (Liu et al., 1998; Turrigiano, 2007) . A corollary of this conceptual framework is that neurons with different activity types differ in the suite of membrane channels that they express and the relative abundance of each channel type. In invertebrates, where individual cells are identifiable and have characteristic activity, this corollary has been emphatically supported and similar evidence exists for vertebrate neurons (Marder, 2011) .
On the other hand, many theoretical studies-again starting in stomatogastric nervous system-have indicated that model neurons and networks can achieve similar activity types with very different complements of membrane and synaptic channels (conductances) (Prinz et al., 2004; Marder and Goaillard, 2006; Marder, 2011) . These theoretical studies were followed by quantitative voltageclamp studies of expressed membrane and synaptic channels, their maximal conductances, and measurements of channel mRNA levels in single neurons (Amendola et al., 2012; Schulz et al., 2007; Tobin et al., 2009) . These studies confirm the theoretical work by showing that even with 3-to 5-fold variation of channel conductances and mRNA levels across individual animals, similar neuronal and network activity is observed.
How can these threads be woven together? The beginnings of an answer arise from the observation that in some cases across individual animals, neuronal maximal conductances (measured in voltage clamp) and mRNA levels of different channel types (measured in single cells) are, for some channels at least, linearly correlated (Schulz et al., 2007; Tobin et al., 2009) . Theoretical studies indicate that such linear correlations of different membrane conductances can maintain activity types (Hudson and Prinz, 2010) . It is a short step then to speculate that homeostatic regulatory mechanisms establish these correlations. But how might such correlations arise homeostatically? Past models of homeostatic regulation of activity type have not explicitly observed or sought such correlations, until recently when O'Leary and colleagues (O'Leary et al., 2013) made a simple neuronal model that showed how abstract ''regulation'' time constants determine correlations in conductance expression at steady state. 
